期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲磺酸加替沙星片和盐酸环丙沙星片随机对照治疗急性细菌感染 被引量：2

Treatment of acute bacterial infection with Gatifloxacin mesylate and Cinrofloxacin: A randomized controlled trial
下载PDF
导出
摘要 目的 :评价甲磺酸加替沙星治疗急性细菌感染的有效性和安全性 .方法 :采用随机对照单盲临床试验的方法 ,完成实验药及对照药治疗急性细菌感染的临床试验 .结果 :甲磺酸加替沙星组与盐酸环丙沙星组的痊愈率分别为 78%(4 3/ 5 5 )和 72 % (38/ 5 3) ;有效率分别为 82 % (4 5 / 5 5 )和 77%(4 1 / 5 3) ,两组痊愈率和有效率无统计学显著差异 (P >0 .0 5 ) .结论 :甲磺酸加替沙星对急性细菌感染有很好的临床疗效和微生物学效果 ,耐受性和安全性好 ,不失为敏感菌感染可选药物 . AIM: To study the efficacy and safety of gatifloxacin mesylate on acute bacterial infection. METHODS: A randomized control clinical trial was performed. Forty patients were randomly divided into two groups, receiving gatifloxacin mesilate and cinrofloxacin respectively. Each subject was given 5 or 7 days treatment. RESULTS: The total cure rate of gatifloxacin mesylate and cinrofloxacin was 78 %(43/55) and 72% (38/53) and the total effective rate 82% (45/55) and 77% (41/53) respectively. There was no significant difference in the efficacy between gatifloxacin mesylate and cinrofloxacin ( P >0.05). CONCLUSION: Gatifloxacin was an effective drug to cure acute bacterial infection.
作者 吴昌归 王汉民 遆新宇 刘颖格 戴艳丽 谭华
机构地区 第四军医大学西京医院呼吸内科 第四军医大学西京医院肾脏内科
出处 《第四军医大学学报》 北大核心 2003年第20期1908-1910,共3页 Journal of the Fourth Military Medical University
关键词 甲磺酸加替沙星 环丙沙星 急性细菌感染 gatifloxacin mesylate ciprofloxacin acute bacterial infections
分类号 R978.1 [医药卫生—药品]
  • 相关文献

参考文献10

  • 1[1]Blondeau JM, Hansen G, Metzler KL, Borsos S, Irvine LB, Blanco L. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin-an advanced fluoroquinolone [J]. Int J Antimicrob Agents, 2003; 22(2): 147-154.
  • 2[2]Hosaka M. Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent [J]. Nippon Yakurigaku Zasshi, 2003; 121(6): 447-456.
  • 3[3]Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones [J]. Eur J Clin Microbiol Infect Dis, 2003; 22(4): 203-221.
  • 4[4]Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans [J]. Arch Ophthalmol, 2003; 121(3): 345-350.
  • 5[5]Correa JC, Badaro R, Bumroongkit C, Mera JR, Dolmann AL, Juarez Martinez LG, Mayrinck LR, Tamez R, Yang JY. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization [J]. Clin Ther, 2003; 25(5): 1453-1468.
  • 6[6]Sato K, Tomioka H, Sano C, Shimizu T, Sano K, Ogasawara K, Cai S, Kamei T. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type Ⅱ alveolar cell lines [J]. J Antimicrob Chemother, 2003; 52(2): 199-203.
  • 7[7]Soler M, Lode H, Baldwin R, Levine JH, Schreurs AJ, van Noord JA, Maesen FP, Zehrer M. Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis [J]. Eur J Clin Microbiol Infect Dis, 2003; 22(3): 144-150.
  • 8[8]Nicholson SC, Wilson WR, Naughton BJ, Gothelf S, Webb CD. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia [J]. Diagn Microbiol Infect Dis, 2002; 44(1): 117-125.
  • 9[9]Gotfried M, Quinn TC, Gothelf S, Wikler MA, Webb CD, Nicholson SC. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study [J]. Diagn Microbiol Infect Dis, 2002; 44(1): 85-91.
  • 10[10]Mandell LA. Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES) [J]. Diagn Microbiol Infect Dis, 2002; 44(1): 65-67.

同被引文献25

  • 1杨俊铃,马忠森,邱晨,杨健,李胜歧,苏立平,钱昱昕,吕媛.五水头孢唑林钠(新泰林)治疗下呼吸道急性细菌性感染的临床研究[J].中国临床药理学杂志,2006,22(5):326-328. 被引量：35
  • 2陆权,陈慧中,杨永弘.关注小儿社区获得性肺炎[J].中华儿科杂志,2007,45(2):81-82. 被引量：33
  • 3Naber KG,Bartnicki A,Bischoff W,et al.Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections[J].Int J Antimicrob Agents,2004,23(Suppl 1):S41-S53.
  • 4Dalhoff A,Schmitz FJ.In vitro antibacterial activity and pharmacodynamics of new quinolones[J].Eur J Clin Microbiol Infect Dis,2003,22(4):203-221.
  • 5Lee SD,Lee SJ,Hwang TK,et al.Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice[J].Int J Antimicrob Agents,2006,28(Suppl 1):S108-S112.
  • 6Schaeffer AJ.The expanding role of fluoroquinolones[J].Am J Med,2002,113(Suppl 1A):45S-54S.
  • 7Blondeau JM,Hansen G,Metzler KL,et al.In vitro susceptibility of 4903 bacterial isolates to gemifloxacin-advanced fluoroquinolone[J].Int J Antimicrob Agents,2003,22(2):147-154.
  • 8Tal S,Guller V,Levi S,et al.Profile and prognosis of febrile elderly patients with bacteremic urinary tract infection[J].J Infect,2005,50(4):296-305.
  • 9Richard GA,Mathew CP,Kirstein JM,et al.Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:Results from a randomized,double-blind,multicenter trial comparing single-dose to 3-day fluoroquinolone regimens[J].Urology,2002,59(3):334-339.
  • 10谢松梅,赵明,杨进波,李娅杰,赵德恒.我国抗菌药物临床疗效评价标准的思考与确定[J].中国临床药理学杂志,2008,24(5):466-468. 被引量：42

引证文献2

二级引证文献3

第四军医大学学报
2003年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部